Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
37628
CAS Number:
94749-08-3
Xinafoate de salmétérol
Purity:
≥ 98 % (dosage par titration, HPLC)
Synonym(s):
4-[1-hydroxy-2-[[6-(4-phénylbutoxy)hexyl]amino]éthyl]-2-(hydroxyméthyl)phénol1-hydroxy-2-naphtoate
Documents
$344.42 /250 mg
Taille
Request Bulk Quote
Informations sur le produit

Salmeterol xinafoate is a long-acting beta-2 adrenergic agonist primarily used in the management of asthma and chronic obstructive pulmonary disease (COPD). This compound is recognized for its ability to provide sustained bronchodilation, making it a critical component in respiratory therapy. Salmeterol xinafoate works by relaxing the muscles in the airways, thereby improving airflow and alleviating symptoms such as wheezing and shortness of breath. Its unique formulation allows for a prolonged therapeutic effect, which is particularly beneficial for patients requiring consistent control of their respiratory conditions.

In addition to its primary use in inhalation therapies, Salmeterol xinafoate is also being explored in various research settings for its potential applications in other areas, such as exercise-induced bronchoconstriction and allergic reactions. The compound's favorable safety profile and efficacy make it a preferred choice among healthcare professionals. With its proven track record in enhancing patient quality of life, Salmeterol xinafoate stands out as a vital agent in respiratory medicine.

Numéro CAS 
94749-08-3
Formule moléculaire
C25H37NO4 · C11H8O3
Poids moléculaire 
603.76
Point de fusion 
138 °C (déc.)
Informations générales
Numéro CAS 
94749-08-3
Formule moléculaire
C25H37NO4 · C11H8O3
Poids moléculaire 
603.76
Point de fusion 
138 °C (déc.)
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

Salmeterol xinafoate is widely utilized in research focused on

  • Asthma Management: This compound is primarily used as a long-acting bronchodilator in asthma inhalers, providing extended relief from respiratory symptoms.
  • Chronic Obstructive Pulmonary Disease (COPD): It helps improve lung function and reduce flare-ups in patients with COPD, enhancing their quality of life.
  • Pharmaceutical Research: Salmeterol xinafoate is studied for its pharmacological properties, aiding researchers in developing new treatments for respiratory diseases.
  • Combination Therapies: Often combined with corticosteroids in inhalers, it optimizes treatment efficacy, allowing for better management of inflammation and bronchoconstriction.
  • Clinical Trials: The compound is frequently involved in clinical trials aimed at assessing new delivery methods or formulations, contributing to advancements in respiratory care.

Citations